Abstract: Disclosed is a blood sample determination method including: emitting light to a measurement specimen prepared by mixing a clotting time measuring reagent and a blood sample suspected to be derived from a subject having lupus anticoagulant or a coagulation factor inhibitor, to obtain optical information about an amount of light from the measurement specimen; obtaining at least one parameter regarding derivative of clot waveform, based on the obtained optical information; and determining, based on a value of the obtained parameter, whether the blood sample is suspected to be a sample derived from a subject having lupus anticoagulant or is suspected to be a sample derived from a subject having a coagulation factor inhibitor.

Abstract: The purpose of the present invention is to provide a biliary stent making it possible to sufficiently exhibit a valve function while reducing the entire length of the biliary stent as compared to conventional ones. The present invention is a biliary stent (1) including a stent body (10), a tubular membrane (30) on one end of the stent body (10) and having a bile outflow port (34), and two support members (40, 50) which at one end (42, 52) are connected to the one end of the stent body (10) and at the other end (44, 54) are connected to the vicinity of the bile outflow port (34).

Abstract: A non-transitory computer-readable recording medium storing a computer program, the computer program comprising: a selecting module configured to select, from among a plurality of biopotential signals, a biopotential signal containing a high proportion of a maternal cardiac potential signal component; an independent component analysis module configured to perform independent component analysis on the plurality of biopotential signals; a periodic signal detection module configured to detect, as a first peak time signal, a signal having periodic peaks from a biopotential signal and to detect, as second peak time signals, one or more signals having periodic peaks among signals output from the independent component analysis module; and an output signal selecting module configured to select from among the one or more second peak time signals a signal having peak times different from those of the first peak time signal.

Abstract: A non-transitory computer-readable recording medium storing a computer program, the computer program comprising: a selecting module configured to select, from among a plurality of biopotential signals, a biopotential signal containing a high proportion of a maternal cardiac potential signal component; an independent component analysis module configured to perform independent component analysis on the plurality of biopotential signals; a periodic signal detection module configured to detect, as a first peak time signal, a signal having periodic peaks from a biopotential signal and to detect, as second peak time signals, one or more signals having periodic peaks among signals output from the independent component analysis module; and an output signal selecting module configured to select from among the one or more second peak time signals a signal having peak times different from those of the first peak time signal.

Abstract: A first calculation unit receives phase characteristics Pa(f) and Pb(f) outputted from frequency transform units, calculates a propagation time difference based on a phase difference between the two phase characteristics in a high-frequency component thereof, and calculates a pulse wave velocity by dividing a difference in the distances of vascular pathways from the heart to respective measurement areas. Meanwhile, a second calculation unit calculates a pulse wave velocity by dividing the stated difference in the distances by a appearance time difference at a predetermined position in respective pulse waveforms obtained by rendering the measurement signals Pa(t) and Pb(t) on a time axis. A comparison unit compares the pulse wave velocities, and in the case where the ratio thereof is outside a predetermined range, an evaluation result indicating that it is possible that a predetermined pathologic change is present in the vascular pathway is outputted to a display processing unit.

Abstract: Disclosed is a material for use in ophthalmologic organ replacement, which is transparent, has controllable physical properties, and can have physical properties suitable for use as an ophthalmic tissue when the hardness of a gel produced from the material or the fluidability of a sol produced from the material at a specific temperature or lower is varied. Specifically disclosed is an ophthalmologic composition capable of forming a gel, which comprises a polyethylene glycol that is represented by formula 1 and has one end modified with a long-chain alkyl group, a polyethylene glycol that is represented by formula 2 and has both ends modified with a long-chain alkyl group, and a solvent. R1—(CH2CH2O-)n1-R2 ??(Formula 1) [In formula 1, R1 represents an alkyl group having 1 to 4 carbon atoms; R2 represents an alkyl group having 16 to 22 carbon atoms; and n1 represents the average number of moles of added oxyethylene groups and falls within the range from 45 to 450.